| Deep learning for prediction of colorectal cancer outcome: a discovery and validation study OJ Skrede, S De Raedt, A Kleppe, TS Hveem, K Liestøl, J Maddison, ... The Lancet 395 (10221), 350-360, 2020 | 532 | 2020 |
| Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative E Stelloo, T Bosse, RA Nout, HJ MacKay, DN Church, HW Nijman, ... Modern pathology 28 (6), 836-844, 2015 | 477 | 2015 |
| DNA polymerase ɛ and δ exonuclease domain mutations in endometrial cancer DN Church, SEW Briggs, C Palles, E Domingo, SJ Kearsey, JM Grimes, ... Human molecular genetics 22 (14), 2820-2828, 2013 | 415 | 2013 |
| A panoply of errors: polymerase proofreading domain mutations in cancer E Rayner, IC Van Gool, C Palles, SE Kearsey, T Bosse, I Tomlinson, ... Nature Reviews Cancer 16 (2), 71-81, 2016 | 367 | 2016 |
| Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer DN Church, E Stelloo, RA Nout, N Valtcheva, J Depreeuw, N Ter Haar, ... Journal of the National Cancer Institute 107 (1), dju402, 2015 | 345 | 2015 |
| Practical guidance for mismatch repair-deficiency testing in endometrial cancer E Stelloo, AML Jansen, EM Osse, RA Nout, CL Creutzberg, D Ruano, ... Annals of Oncology 28 (1), 96-102, 2017 | 344 | 2017 |
| POLE proofreading mutations elicit an antitumor immune response in endometrial cancer IC van Gool, FA Eggink, L Freeman-Mills, E Stelloo, E Marchi, M de Bruyn, ... Clinical Cancer Research 21 (14), 3347-3355, 2015 | 329 | 2015 |
| Interpretation of somatic POLE mutations in endometrial carcinoma A León‐Castillo, H Britton, MK McConechy, JN McAlpine, R Nout, ... The Journal of pathology 250 (3), 323-335, 2020 | 325 | 2020 |
| Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study E Domingo, L Freeman-Mills, E Rayner, M Glaire, S Briggs, L Vermeulen, ... The lancet Gastroenterology & hepatology 1 (3), 207-216, 2016 | 323 | 2016 |
| Clinicopathological and molecular characterisation of ‘multiple‐classifier’endometrial carcinomas A León‐Castillo, E Gilvazquez, R Nout, VT Smit, JN McAlpine, ... The Journal of pathology 250 (3), 312-322, 2020 | 320 | 2020 |
| Insulin‐like growth factor ligands, receptors, and binding proteins in cancer E Foulstone, S Prince, O Zaccheo, JL Burns, J Harper, C Jacobs, ... The Journal of Pathology: A Journal of the Pathological Society of Great …, 2005 | 318 | 2005 |
| Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis D Rosmarin, C Palles, D Church, E Domingo, A Jones, E Johnstone, ... Journal of Clinical Oncology 32 (10), 1031-1039, 2014 | 281 | 2014 |
| Evaluation of PIK3CA Mutation As a Predictor of Benefit From Nonsteroidal Anti-Inflammatory Drug Therapy in Colorectal Cancer E Domingo, DN Church, O Sieber, R Ramamoorthy, Y Yanagisawa, ... Journal of clinical oncology 31 (34), 4297-4305, 2013 | 245 | 2013 |
| The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome EJ Crosbie, NAJ Ryan, MJ Arends, T Bosse, J Burn, JM Cornes, ... Genetics in Medicine 21 (10), 2390-2400, 2019 | 235 | 2019 |
| Promises and challenges of adoptive T-cell therapies for solid tumours M Morotti, A Albukhari, A Alsaadi, M Artibani, JD Brenton, SM Curbishley, ... British journal of cancer 124 (11), 1759-1776, 2021 | 227 | 2021 |
| A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer HH Workel, JM Lubbers, R Arnold, TM Prins, P van der Vlies, K de Lange, ... Cancer immunology research 7 (5), 784-796, 2019 | 201 | 2019 |
| CD103+ tumor-infiltrating lymphocytes are tumor-reactive intraepithelial CD8+ T cells associated with prognostic benefit and therapy response in cervical cancer FL Komdeur, TM Prins, S van de Wall, A Plat, GBA Wisman, H Hollema, ... Oncoimmunology 6 (9), e1338230, 2017 | 179 | 2017 |
| Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial RS Kerr, S Love, E Segelov, E Johnstone, B Falcon, P Hewett, A Weaver, ... The Lancet Oncology 17 (11), 1543-1557, 2016 | 169 | 2016 |
| Frequent homologous recombination deficiency in high-grade endometrial carcinomas MM De Jonge, A Auguste, LM van Wijk, PC Schouten, M Meijers, ... Clinical Cancer Research 25 (3), 1087-1097, 2019 | 165 | 2019 |
| Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for … FA Eggink, IC Van Gool, A Leary, PM Pollock, EJ Crosbie, L Mileshkin, ... Oncoimmunology 6 (2), e1264565, 2017 | 143 | 2017 |